EUVIMEDEUVIMED entdecken
Open Access

Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction

Christopher W Coyle, Kristopher A Knight, Harrison C Brown, Stephan N George, Gabriela Denning, Gianna M Branella, Kenneth C Childers, P Clint Spiegel, H Trent Spencer, Christopher B Doering

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2023.11.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Christopher W Coyle und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Systems Pharmacology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University…. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Emory University, Hemophilia of Georgia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Laboratory resurrection of ancient coagulation factor (F) IX variants generated through ancestral sequence reconstruction led to the discovery of a FIX variant, designated An96, which possesses enhanced specific activity independent of and additive to that provided by human p.Arg384Lys, referred to as FIX-Padua. OBJECTIVES: The goal of the current study was to identify the amino acid substitution(s) responsible for the enhanced activity of An96 and create a humanized An96 FIX transgene for gene therapy application. METHODS: Reductionist screening approaches, including domain swapping and scanning residue substitution, were used and guided by one-stage FIX activity assays. In vitro characterization of top candidates included recombinant high-purity preparation, specific activity determination, and enzyme kinetic analysis. Final candidates were packaged into adeno-associated viral (AAV) vectors and delivered to hemophilia B mice. RESULTS: Five of 42 total amino acid substitutions in An96 appear sufficient to retain the enhanced activity of An96 in an otherwise human FIX variant. Additional substitution of the Padua variant further increased the specific activity 5-fold. This candidate, designated ET9, demonstrated 51-fold greater specific activity than hFIX. AAV2/8-ET9 treated hemophilia B mice produced plasma FIX activities equivalent to those observed previously for AAV2/8-An96-Padua, which were 10-fold higher than AAV2/8-hFIX-Padua. CONCLUSION: Starting from computationally inferred ancient FIX sequences, novel amino acid substitutions conferring activity enhancement were identified and translated into an AAV-FIX gene therapy cassette demonstrating high potency. This ancestral sequence reconstruction discovery and sequence mapping refinement approach represents a promising platform for broader protein drug and gene therapy candidate optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXHemophilia BHumansMiceAnimalsKineticsGenetic TherapyAmino Acid SubstitutionGenetic VectorsDependovirus

Stichwörter der Autor:innen

adeno-associated virusfactor IXgene therapyhemophilia Bprotein engineering

Substanzen

Factor IX

Autor:innen und Institutionen

  • Molecular and Systems Pharmacology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Expression Therapeutics, Inc, Atlanta, Georgia, USA.
  • Cancer Biology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Chemistry Department, Western Washington University, Bellingham, Washington, USA.
  • Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA.
  • Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA. Electronic address: cdoerin@emory.edu.

Förderung

  • NHLBI NIH HHS
  • Emory University
  • Hemophilia of Georgia
  • National Institutes of Health
  • Children's Healthcare of Atlanta
  • National Hemophilia Foundation
  • National Heart, Lung, and Blood Institute
  • Georgia Institute of Technology

Zitieren

APA

Coyle, C. W., Knight, K. A., Brown, H. C., George, S. N., Denning, G., Branella, G. M., Childers, K. C., Spiegel, P. C., Spencer, H. T., & Doering, C. B. (2024). Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.11.010

Vancouver

Coyle CW, Knight KA, Brown HC, George SN, Denning G, Branella GM, et al. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2023.11.010

BibTeX
@article{Coyle2024,
  author = {Coyle, Christopher W and Knight, Kristopher A and Brown, Harrison C and George, Stephan N and Denning, Gabriela and Branella, Gianna M and Childers, Kenneth C and Spiegel, P Clint and Spencer, H Trent and Doering, Christopher B},
  title = {Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2023.11.010}
}
Kostenlos starten →